Spots Global Cancer Trial Database for carcinoid tumors
Every month we try and update this database with for carcinoid tumors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs) | NCT02359500 | Neuroendocrine ... Carcinoid Tumor... | 68Ga-DOTATOC PE... | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | NCT00947167 | Neuroendocrine ... Carcinoid Tumor... Adrenal Gland T... Neuroblastoma Pancreatic Neur... Multiple Endocr... | pertuzumab erlotinib | - | Stanford University | |
| Endoscopic Treatment of Bronchial Carcinoid Tumors | NCT03723499 | Carcinoid Tumor | Medical data co... | 18 Years - | Centre Hospitalier Universitaire de Saint Etienne | |
| A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | NCT00947167 | Neuroendocrine ... Carcinoid Tumor... Adrenal Gland T... Neuroblastoma Pancreatic Neur... Multiple Endocr... | pertuzumab erlotinib | - | Stanford University | |
| Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) | NCT01253161 | Neuroendocrine ... Carcinoid Tumor... | Pasireotide Lon... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors | NCT01373736 | Pheochromocytom... Neuroblastoma Paraganglioma Medullary Thyro... Carcinoid Tumor... | 123I-meta-iodob... | - | Vancouver Coastal Health | |
| Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) | NCT01253161 | Neuroendocrine ... Carcinoid Tumor... | Pasireotide Lon... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors | NCT01731925 | Carcinoid Tumor... | Lanreotide Placebo (for su... Sunitinib | 18 Years - | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma | NCT00580320 | Melanoma Soft Tissue Sar... Parathyroid Car... Small Cell Carc... Carcinoid Tumor... | Dacarbazine and... | 18 Years - | Virginia Commonwealth University | |
| Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres | NCT02859064 | Neuroendocrine ... Gastrointestina... Carcinoid Tumor... | Lanreotide Y-90 microspher... | 18 Years - | SCRI Development Innovations, LLC | |
| Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion | NCT00227136 | Carcinoid Tumor... Neuroendocrine ... | 5-Hydroxy-Trypt... | 18 Years - | Western University, Canada | |
| Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines) | NCT03622333 | Small Intestina... | Research of con... | 18 Years - | CHU de Reims | |
| Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | NCT02575300 | Carcinoid Tumor... Pancreatic NET | Ibrutinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres | NCT02859064 | Neuroendocrine ... Gastrointestina... Carcinoid Tumor... | Lanreotide Y-90 microspher... | 18 Years - | SCRI Development Innovations, LLC | |
| Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma | NCT00580320 | Melanoma Soft Tissue Sar... Parathyroid Car... Small Cell Carc... Carcinoid Tumor... | Dacarbazine and... | 18 Years - | Virginia Commonwealth University | |
| GA-68 DOTA-TOC of Somatostatin Positive Malignancies | NCT02177773 | Neuroendocrine ... Paraganglioma Carcinoid Tumor... Neuroblastoma | Computed Tomogr... Gallium Ga 68-E... Magnetic Resona... Positron Emissi... | 2 Years - | University of California, San Francisco | |
| A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | NCT00947167 | Neuroendocrine ... Carcinoid Tumor... Adrenal Gland T... Neuroblastoma Pancreatic Neur... Multiple Endocr... | pertuzumab erlotinib | - | Stanford University | |
| Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion | NCT00227136 | Carcinoid Tumor... Neuroendocrine ... | 5-Hydroxy-Trypt... | 18 Years - | Western University, Canada | |
| 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors | NCT01373736 | Pheochromocytom... Neuroblastoma Paraganglioma Medullary Thyro... Carcinoid Tumor... | 123I-meta-iodob... | - | Vancouver Coastal Health | |
| Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines) | NCT03622333 | Small Intestina... | Research of con... | 18 Years - | CHU de Reims |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
